Clinical Trial Update: Atezolizumab+Bevacizumab+SBRT in Unresectable HCC [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing a combination of atezolizumab, bevacizumab, and SBRT for unresectable hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Unresectable Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING